Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ciprofloxacin · 3 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Ciprofloxacin Extended-Release Tablets 500 mg |
| 2 | ACTIVE_COMPARATOR | Cipro® XR Tablets 500 mg |
| Name | Type | Description |
|---|---|---|
| Ciprofloxacin Extended-Release Tablets 500 mg | DRUG | 500mg, single dose fasting |
| Cipro® XR Tablets (500 mg | DRUG | 500mg, single dose fasting |
| Ciprofloxacin Extended-Release Tablets 1000 mg | DRUG | 1000mg, single dose fasting |
| Cipro® XR Tablets 1000 mg | DRUG | 1000mg, single dose fasting |
Inclusion Criteria: 1. Age: 18 years and older. 2. Sex: Male and/or non-pregnant, non-lactating female. 1. Women of childbearing potential must have negative serum beta human chorionic gonadotropin (β-HCG) pregnancy tests performed within 14 days prior to the start of the study and on the eveni...
Ciprofloxacin is a small molecule drug developed by Viatris Inc. (ticker VTRS). It is being studied in Phase 1 clinical development. The specific therapeutic indication for this program is not disclosed. The drug is also known as Ciprofloxacin Extended-Release Tablets 1000 mg and Ciprofloxacin Extended-Release Tablets 500 mg.
Ciprofloxacin is developed by Viatris Inc., which trades under the ticker symbol VTRS. Viatris is the sponsor of the clinical program for this extended-release tablet formulation.
Ciprofloxacin is in Phase 1 clinical development. All three of its recorded trials are Phase 1 studies, and all three have been completed. No active trials are currently listed for this program.
Ciprofloxacin has been evaluated in three completed Phase 1 trials: NCT00650351, a food study of the 1000 mg extended-release tablet; NCT00649662, a fasting study of the 1000 mg tablet; and NCT00649155, a fasting study of the 500 mg tablet. All enrolled healthy adult volunteers in the United States.
Yes. Ciprofloxacin is also known as Ciprofloxacin Extended-Release Tablets 1000 mg and Ciprofloxacin Extended-Release Tablets 500 mg. These names refer to the same extended-release tablet formulations studied in the Phase 1 program.
The three completed Phase 1 trials of Ciprofloxacin enrolled a total of 107 participants. NCT00650351 enrolled 35, NCT00649662 enrolled 36, and NCT00649155 enrolled 36. All participants were healthy volunteers aged 18 years and older, and the studies were active-controlled.